Condition: Recurrent Malignant Glioma · Brain Glioblastoma · Sponsor: Oblato, Inc.
This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease. Patients with unequivocal recurrence (first or greater) established by MRI and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| St. Joseph's Hospital and Medical Center | Phoenix, Arizona, United States | — |
| Providence Saint John's Health Center - John Wayne Cancer Institute | Santa Monica, California, United States | — |
| Swedish Medical Center | Englewood, Colorado, United States | — |
| AdventHealth Orlando | Orlando, Florida, United States | — |
| University of Iowa | Iowa City, Iowa, United States | — |
| Norton Healthcare | Louisville, Kentucky, United States | — |
| Henry Ford Health System | Detroit, Michigan, United States | — |
| Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem, North Carolina, United States | — |
| The University of Toledo | Toledo, Ohio, United States | — |
| The University of Oklahoma | Oklahoma City, Oklahoma, United States | — |
| Lifespan Office of Research | Providence, Rhode Island, United States | — |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04388475